Company Profile

Lumen Therapeutics LLC
Profile last edited on: 6/4/19      CAGE: 42PZ9      UEI:

Business Identifier: Drugs development based on polymers of L-arginine
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

325 Sharon Park Drive Suite 753
Menlo Park, CA 94025
   (650) 450-4439
Location: Single
Congr. District: 18
County: San Mateo

Public Profile

Lumen Therapeutics had been a development stage biopharmaceutical company focused on proprietary drugs based on oligo-L-arginine. At the time of Lume's SBIR Phase I in 2010, the company's lead product has completed a Phase I/IIa clinical trial for the prevention of vein graft failure after bypass graft surgery. Lumen’s lead product (LT-1951) exploited the unique ability of small peptides containing L‑arginine to penetrate into blood vessels and prevent vascular stenosis by increasing the local concentration of nitric oxide. Such peptides have been shown to block the occurrence of vascular stenosis in animals that have undergone vein graft procedures similar to those used in CABG, PABG and AVS. Lumen's founders - the Stanford University scientists who did early preclinical research in this field -- discovered and patented Lumen's lead product candidates. Thes expectation was that the proprietary peptide agents would prove to be highly effective in the prevention of vascular stenosis in CABG, PABG, and AVS. The evidence would seem to sugges that the firm is nolonger operation

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $195,859
Project Title: Therapeutic To Improve Maturation And Performance Of Arteriovenous Fistulae

Key People / Management

  Paul L McGrane -- Director and Founder

  Michael Danaher -- Director

  C Garrison Fathman -- Director and Founder

  Ferid Murad -- Member of the Scientific Advisory Board

Company News

There are no news available.